BIOFLOW-III Israel Satellite Registry

Inclusion Criteria: * Patients with diabetes mellitus Type 1 or 2 * Stable coronary patients with moderate-severe symptomatic angina (CCS ≥II) and evidence of myocardial ischemia per non- invasive test (nuclear or echo) or patients with 'silent' myocardial ischemia and a large (e.g. \>10% of myocardium) territory of myocardium in jeopardy (nuclear or echo) * Subject signed informed consent * Subject is geographically stable and willing to participate at all follow up assessments * Subject is ≥ 18 years of age Exclusion Criteria: * Subject did not sign informed consent * Left main disease * Complex bifurcations * Ostial lesions * Three vessel disease * Large visible thrombus * Heavy calcified lesions needing atherectomy or cutting balloon dilatation * Syntax Score ≥33 * Active bleeding * Sepsis * Chronic total Occlusion * Bleeding tendency obviate dual anti platelet (DAP) intake for one year * Hb\<11/Plts,100.000/WBC\<4000 or \>11.00 * Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years following index procedure. (Female subjects of child- bearing potential must have a negative pregnancy test done within 28 days prior to the index procedure and contraception must be used during participation in this trial) * Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and prasugrel and ticlopidine, inclusive), sirolimus, poly (L-lactide) poly (DL-lac…